Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen

Sutaria,Dhruvitkumar; Grandhi,Balagangadhar  Karthik; Thakkar,Arvind; Wang,Jeffrey; Prabhu,Sunil

doi:10.3892/ijo.2012.1636

Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen

Authors:
- Dhruvitkumar Sutaria
- Balagangadhar Karthik Grandhi
- Arvind Thakkar
- Jeffrey Wang
- Sunil Prabhu
View Affiliations

Affiliations: Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA
Published online on: September 21, 2012 https://doi.org/10.3892/ijo.2012.1636
Pages: 2260-2268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is the fourth largest cause of cancer deaths in the Unites States and the prognosis is grim with <5% survival chances upon diagnosis. The objective of this study was to assess the combined chemopreventive effect of solid lipid nanoparticle (SLN) encapsulated drugs aspirin (ASP), curcumin (CUR) and free sulforaphane (SFN) for the chemoprevention of pancreatic cancer. Experiments were carried out (1) to evaluate the feasibility of encapsulation of these chemopreventive agents within solid lipid systems and (2) to measure the synergistic effects of a combination of ASP with CUR in SLNs mixed with free SFN against cell proliferation and apoptosis in pancreatic cancer cells, MIA PaCa-2 and Panc-1. The SLNs were prepared using a modified solvent evaporation technique and were characterized for particle sizing, encapsulation efficiency and drug release. ASP and CUR SLNs were formulated within the particle size range of 150‑250 nm and were found to have an encapsulation efficiency of 85 and 69%, respectively. Sustained release of drugs over a 96 h period from SLNs was observed. The SLNs were stable over a 3-month storage period at room temperature. Cell viability studies demonstrated that combinations of low doses of ASP SLN (25 µM), CUR SLN (2.5 µM) and free SFN (5 µM) significantly reduced cell viability by 43.6 and 48.49% in MIAPaca-2 and Panc-1 cell lines, respectively. Furthermore, increased apoptosis of 61.3 and 60.37% was found in MIA Paca-2 and Panc-1 cell lines, respectively, in comparison to the individual doses administered. Synergistic effects were demonstrated using MTS and apoptosis assays. Thus, this study successfully demonstrated the feasibility of using a solid lipid nanoparticulate system for the first time to deliver this novel combination chemoprevention regimen, providing valuable evidence for the usability of nanotechnology-based drug regimens towards pancreatic cancer chemoprevention.

View Figures

View References

1.	R SiegelD NaishadhamA JemalCancer statistics, 2012CA Cancer J Clin621029201210.3322/caac.20138
2.	V FendrichChemoprevention of pancreatic cancer-one step closerLangenbecks Arch Surg397495505201210.1007/s00423-012-0916-x22350613
3.	CD LogsdonJL AbbruzzeseChemoprevention of pancreatic cancer: ready for the clinic?Cancer Prev Res (Phila)313751378201010.1158/1940-6207.CAPR-10-021621084259
4.	SS HusainIL SzaboAS TamawskiNSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of actionAm J Gastroenterol97542553200210.1111/j.1572-0241.2002.05528.x11922545
5.	AT ChanEL GiovannucciES SchernhammerA prospective study of aspirin use and the risk for colorectal adenomaAnn Intern Med140157166200410.7326/0003-4819-140-3-200402030-0000614757613
6.	A KokawaH KondoT GotodaIncreased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitorsCancer91333338200110.1002/1097-0142(20010115)91:2%3C333::AID-CNCR1006%3E3.0.CO;2-N11180079
7.	EJ JacobsCJ ConnellC RodriguezAV PatelEE CalleMJ ThunAspirin use and pancreatic cancer mortality in a large United States cohortJ Natl Cancer Inst96524528200410.1093/jnci/djh08415069114
8.	SD StanSV SinghRE BrandChemoprevention strategies for pancreatic cancerNat Rev Gastroenterol Hepatol7347356201020440279
9.	ML KuoTS HuangJK LinCurcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cellsBiochim Biophys Acta131795100199610.1016/S0925-4439(96)00032-48950193
10.	FH SarkarS BanerjeeY LiPancreatic cancer: pathogenesis, prevention and treatmentToxicol Appl Pharmacol224326336200710.1016/j.taap.2006.11.00717174370
11.	G SaT DasAnti cancer effects of curcumin: cycle of life and deathCell Div314200810.1186/1747-1028-3-1418834508
12.	L MoragodaR JaszewskiAP MajumdarCurcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cellsAnticancer Res21873878200111396178
13.	DW LiJP LiuYW MaoCalcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activationMol Biol Cell1644374453200510.1091/mbc.E05-01-001016000378
14.	JA RomashkovaSS MakarovNF-kappaB is a target of AKT in anti-apoptotic PDGF signallingNature4018690199910.1038/4347410485711
15.	NV MatusheskiJA JuvikEH JefferyHeating decreases epithiospecifier protein activity and increases sulforaphane formation in broccoliPhytochemistry6512731281200410.1016/j.phytochem.2004.04.01315184012
16.	G KallifatidisV RauschB BaumannSulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced anti-apoptotic signallingGut58949963200910.1136/gut.2008.14903918829980
17.	JW LampeSulforaphane: from chemoprevention to pancreatic cancer treatment?Gut58900902200910.1136/gut.2008.16669419520886
18.	CV RaoHL NewmarkBS ReddyChemopreventive effect of farnesol and lanosterol on colon carcinogenesisCancer Detect Prev26419425200210.1016/S0361-090X(02)00119-812507226
19.	P ZhouSW ChengR YangB WangJ LiuCombination chemoprevention: future direction of colorectal cancer preventionEur J Cancer Prev21231240201210.1097/CEJ.0b013e32834dbbfd22456425
20.	A ChaudharyJ WangS PrabhuDevelopment and validation of a high-performance liquid chromatography method for the simultaneous determination of aspirin and folic acid from nano-particulate systemsBiomed Chromatogr24919925201020033881
21.	S PrabhuLP TranGV BetageriEffect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implantsDrug Deliv12393398200510.1080/1071754059096887316253955
22.	L Brannon-PeppasJO BlanchetteNanoparticle and targeted systems for cancer therapyAdv Drug Deliv Rev5616491659200410.1016/j.addr.2004.02.01415350294
23.	RH MüllerK MäderS GohlaSolid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the artEur J Pharm Biopharm50161177200010840199
24.	M UnerG YenerImportance of solid lipid nanoparticles (SLN) in various administration routes and future perspectivesInt J Nanomed2289300200718019829
25.	H YuanJ ChenYZ DuFQ HuS ZengHL ZhaoStudies on oral absorption of stearic acid SLN by a novel fluorometric methodColloids Surf B Biointerfaces58157164200710.1016/j.colsurfb.2007.03.00217446050
26.	A ChaudharyD SutariaY HuangJ WangS PrabhuChemoprevention of colon cancer in a rat carcinogenesis model using a novel nanotechnology-based combined treatment systemCancer Prev Res (Phila)416551664201110.1158/1940-6207.CAPR-11-0129
27.	BS ReddyJ NayiniK TokumoJ RigottyE ZangG KelloffChemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in dietCancer Res50256225681990
28.	A MigliettaR CavalliC BoccaL GabrielMR GascoCellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxelInt J Pharm2106167200010.1016/S0378-5173(00)00562-711163988
29.	F YanC ZhangY ZhengThe effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicityNanomedicine6170178201010.1016/j.nano.2009.05.00419447200